ARTICLE | Product Development
NIH, Hubei trials of remdesivir could be more telling than Gilead’s
February 28, 2020 12:56 AM UTC
Updated on Mar 18, 2020 at 1:30 AM UTC
A look at the five Phase II and III clinical trials testing remdesivir to treat COVID-19 suggests the Gilead-sponsored trials may be less informative about efficacy.
Three different organizations are sponsoring the studies. NIH’s adaptive Phase II trial and the two Phase III trials being run by China-Japan Friendship Hospital are blinded trials with placebo control arms; whereas the two Phase III studies that Gilead Sciences Inc. (NASDAQ:GILD) announced Wednesday are both open-label. One of the Gilead trials has no control arm, while the other has a non-blinded standard-of-care arm (see “COVID-19 Roundup”). ...